Real-world data support the safety profile of the anti-fibrotic medications Esbriet (pirfenidone) and Ofev (nintedanib) in people with idiopathic pulmonary fibrosis (IPF), according to a new study. More than half of patients experienced treatment-related adverse events, the majority being non-severe gastrointestinal symptoms. Rare cases of serious heart-related…
AbbVie’s portfolio of antibodies for the potential treatment of idiopathic pulmonary fibrosis (IPF) now includes DJS-002 — a first-in-class antibody directed against lysophosphatidic acid receptor-1 (LPAR1), a protein thought to drive the progression of IPF and other fibrotic diseases. This was made possible by AbbVie’s estimated $250 million acquisition of…
BenevolentAI has identified a new treatment target for idiopathic pulmonary fibrosis (IPF) that will be added to AstraZeneca’s therapeutic discovery portfolio. This is the third IPF target identified by the platform for the biopharmaceutical company following previous discoveries. Another AI-generated target for chronic kidney disease (CKD)…
Algernon Pharmaceuticals’ experimental oral therapy NP-120 (ifenprodil) significantly reduced coughing in people with idiopathic pulmonary fibrosis (IPF), according to a new analysis of top-line data from a proof-of-concept Phase 2a clinical trial. The analysis showed the therapy was much more effective at easing cough than previously reported. NP-120’s “potential…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases have been selected to receive a Horizon Therapeutics‘ #RAREis Global Advocate Grant. Winners of this year’s inaugural awards are spread across nine countries and represent a total of 29 rare…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Tvardi Therapeutics’ TTI-101 for the treatment of idiopathic pulmonary fibrosis (IPF). TTI-101 is a small molecule, given orally, that acts as a direct inhibitor of STAT3, an inflammatory protein that plays a role in the…
Abnormally high levels of the signaling molecule interleukin 19 (IL-19) were detected in lung tissues from both mice and humans with idiopathic pulmonary fibrosis (IPF) in a recent study. These findings indicate that IL-19 promotes IPF progression by activating the transforming growth factor-beta pathway, a key mediator of tissue…
Supplementary oxygen using a high‐flow nasal cannula boosts exercise endurance more effectively than standard devices in idiopathic pulmonary fibrosis (IPF) patients with suboptimal blood-oxygen levels, a small trial reported. The study, “Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial,” was…
In commemoration of the International Quality of Life Month happening in January, the Pulmonary Fibrosis Foundation (PFF) is calling attention to the educational resources it offers, which are designed to support and improve the lives of people with pulmonary fibrosis (PF). “This January, start the New Year on…
The first patient has been enrolled in a pivotal Phase 2b trial investigating the safety and effectiveness of Horizon Therapeutics’ oral medicine candidate HZN-825 in people with idiopathic pulmonary fibrosis (IPF). The trial (NCT05032066) aims to enroll approximately 360 people with IPF, ages 18–80, whose disease symptoms…
Get regular updates to your inbox.
